NDC00409-3414-11: METOCLOPRAMIDE INJECTION.
The METOCLOPRAMIDE INJECTION is a the manufacturer industrial component. Key specifications include administration: INTRAMUSCULAR OR INTRAVENOUS, primary_container_type: VIAL, supplementary_features: NOTE: F, protective_storage_feature: SUBJECT TO DAMAGE BY FREEZING, medical_designation_and_grade: UNITED STATES PHARMACOPEIA, total_primary_container_quantity: 25. This part is cataloged in the U.S.
Government catalog under NSN 6505-01-268-3738, indicating validated use in U.S. government and defense logistics supply chains. Available through authorized enterprise resellers and TPM (Third Party Maintenance) channels.
Verify compatibility with your specific system configuration before ordering.
| administration | INTRAMUSCULAR OR INTRAVENOUS |
| primary_container_type | VIAL |
| supplementary_features | NOTE: F |
| protective_storage_feature | SUBJECT TO DAMAGE BY FREEZING |
| medical_designation_and_grade | UNITED STATES PHARMACOPEIA |
| total_primary_container_quantity | 25 |
| primary_container_content_quantity | 2.000 MILLILITERS |
| active_medicament_medicinal_strength | 5.000 MILLIGRAMS METOCLOPRAMIDE EQUIVALENT PER MILLILITER |
| part_name_assigned_by_controlling_agency | METOCLOPRAMIDE INJECTION USP 5MG/ML 2ML VIAL 25S |
| NSN | 6505-01-268-3738 |
| ADMINISTRATION | INTRAMUSCULAR OR INTRAVENOUS |
| PRIMARY CONTAINER CONTENT QUANTITY | 2.000 MILLILITERS |
| SUPPLEMENTARY FEATURES | NOTE: F |
| MEDICAL DESIGNATION AND GRADE | UNITED STATES PHARMACOPEIA |
| PRIMARY CONTAINER TYPE | VIAL |
| PROTECTIVE STORAGE FEATURE | SUBJECT TO DAMAGE BY FREEZING |
| PART NAME ASSIGNED BY CONTROLLING AGENCY | METOCLOPRAMIDE INJECTION USP 5MG/ML 2ML VIAL 25S |
| ACTIVE MEDICAMENT MEDICINAL STRENGTH | 5.000 MILLIGRAMS METOCLOPRAMIDE EQUIVALENT PER MILLILITER |
| TOTAL PRIMARY CONTAINER QUANTITY | 25 |